Tae‐You Kim

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +13

Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

Michael Ohh, Cheol Won Park, Mircea Ivan et al. · Nature Cell Biology · 2000 · 1.6K citations

Life Sciences, Cell Biology, Molecular Biology +12

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · JAMA Oncology · 2020 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer

Hae‐Ock Lee, Yourae Hong, Hakki Emre Etlioglu et al. · Nature Genetics · 2020 · 1K citations

Medicine, Cancer Biology, Molecular Biology +16